CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers

Background Programmed cell death protein-1 (PD-1) expression has been associated with activation and exhaustion of both the CD4 and CD8 populations in advanced non-small cell lung cancer (aNSCLC). Nevertheless, the impact of the balance between circulating CD8+PD-1+ and CD4+PD-1+ in patients treated...

Full description

Saved in:

Bibliographic Details
Main Authors:	Francois-Xavier Danlos, Aurélien Marabelle, Roberto Ferrara, Benjamin Besse, Lydie Cassard, Nathalie Chaput, Aude Desnoyer, Boris Duchemann, Marie Naigeon, Edouard Auclin, Jean-Mehdi Jouniaux, Lisa Boselli, Jonathan Grivel, Laura Mezquita, Caroline Caramella
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2022-02-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/10/2/e004012.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
by: Fabien Forest, et al.
Published: (2020-10-01)

Infiltration of CD8+ cytotoxic T-cells and expression of PD-1 and PD-L1 in ovarian clear cell carcinoma
by: Mengdi Fu, et al.
Published: (2025-02-01)

Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
by: Francois Ghiringhelli, et al.
Published: (2021-06-01)

CD57+ EMRA CD8+ T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy
by: Cécile Gonnin, et al.
Published: (2024-12-01)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
by: Solange Peters, et al.
Published: (2023-10-01)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
by: Valerie Chew, et al.
Published: (2020-10-01)

Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles
by: Jun Deng, et al.
Published: (2023-12-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Serum PD-1 regulation and PD-1 expression of CD4+Foxp3+ regulatory T cells in patients in thyroid eye disease associated with immunosuppression treatment
by: Atsushi Sakai, et al.
Published: (2024-12-01)

Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL
by: Tingting Zhang, et al.
Published: (2022-04-01)

Pan-cancer analysis of CD274 (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression
by: Brennan Decker, et al.
Published: (2021-06-01)

Downregulating LKB1 in bone marrow mesenchymal stem cells could inhibit CD4+ T cell proliferation via the PD-1/PD-L1 signaling pathway
by: Yaqin Zhang, et al.
Published: (2024-11-01)

Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment
by: Xu Liu, et al.
Published: (2024-12-01)

Association of PD-1 and PD-L1 Genetic Polymorphyisms with Type 1 Diabetes Susceptibility
by: Chenyue Qian, et al.
Published: (2018-01-01)

Expression and relationship of PD-L1, CD24, and CD47 in hepatitis B virus associated hepatocellular carcinoma
by: Aiping Lin, et al.
Published: (2024-12-01)

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells
by: Susan N Christo, et al.
Published: (2024-01-01)

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma
by: Mengjia Song, et al.
Published: (2024-12-01)

A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01)

Increased PD-1 expression in livers associated with PD-1-antibody-induced hepatotoxicity
by: Miro Saarela, et al.
Published: (2025-01-01)

PD-1 suppresses human CD38+ circulating Tfr cells and regulates humoral immunity
by: Heng Zhang, et al.
Published: (2025-01-01)

Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy
by: Vishnu Vijay Vijayan, et al.
Published: (2024-12-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Optimizing PD-L1/PD-1 therapies: Immune checkpoint inhibitors in nasopharyngeal carcinoma
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Periodontitis promotes tumor growth and immune evasion via PD-1/PD-L1
by: Suli Wang, et al.
Published: (2024-11-01)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
by: Alberto Puccini, et al.
Published: (2020-05-01)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
by: Niklas Klümper, et al.
Published: (2023-12-01)

Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1
by: Pauline Malinge, et al.
Published: (2024-12-01)

PD-1 does not mark tumor-infiltrating CD8+ T cell dysfunction in human gastric cancer
by: Ying Wang, et al.
Published: (2020-10-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

PD-L1 antibodies-armed exosomal vaccine for enhanced cancer immunotherapy by simultaneously in situ activating T cells and blocking PD-1/PD-L1 axis
by: Xinyue Dai, et al.
Published: (2022-12-01)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
by: Andrew Coxon, et al.
Published: (2022-12-01)

Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies
by: Annapaola Montagner, et al.
Published: (2024-12-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

Activated CD27+PD-1+ CD8 T Cells and CD4 T Regulatory Cells Dominate the Tumor Microenvironment in Refractory Celiac Disease Type II
by: Tessa Dieckman, et al.
Published: (2025-01-01)

ADA/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB
by: Ornella Franzese, et al.
Published: (2024-12-01)

Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models
by: Taiki Kurino, et al.
Published: (2020-05-01)

The Potential of PD-1 and PD-L1 as Prognostic and Predictive Biomarkers in Colorectal Adenocarcinoma Based on TILs Grading
by: Nur Rahmah Rasyid, et al.
Published: (2024-11-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

The Increase of Circulating PD-1- and PD-L1-Expressing Lymphocytes in Endometriosis: Correlation with Clinical and Laboratory Parameters
by: Monika Walankiewicz, et al.
Published: (2018-01-01)

PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
by: Menglei Jin, et al.
Published: (2024-11-01)